SF500
SF500 is an Argentina-based accelerator and venture capital fund founded in 2022 that invests in Latin American synthetic biology startups addressing human and planetary preservation challenges.
- Company typePrivate
- Founded2022
- HeadquartersRosario, Argentina
- Headcount1–10
- GTM typeB2B
- OfferingServices
What SF500 does
SF500 is a privately held accelerator and venture capital fund headquartered in Rosario, Argentina, founded in 2022. The firm targets synthetic biology (synbio) startups across Latin America whose work addresses global challenges tied to human and planetary preservation. By combining accelerator-style programmatic support with capital deployment, SF500 seeks to occupy a specialized niche in the LATAM venture market where dedicated synbio funding is limited.
The firm operates with a small team of 1-10 employees and maintains a web presence at sf500.com.ar, although the source data for that domain returned only a loading/verification page rather than detailed program information. No portfolio companies, fund size, AUM, ticket sizes, accelerator cohort cadence, mentor network, LP composition, or investment stages were disclosed in the available source material. As a result, the operational mechanics of the accelerator program — selection criteria, duration, equity terms, follow-on policy — and the fund's financial profile remain unspecified.
The business model is presumed to follow standard venture fund economics: management fees on committed capital plus carried interest on realized gains, with the accelerator component potentially generating equity stakes in cohort companies. However, without disclosed fund close data, portfolio list, or revenue figures, the magnitude and current stage of these revenue streams cannot be confirmed from the input.
SF500 firmographics
Firmographics- Name
- SF500
- Website
- https://sf500.com.ar
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SF500 is an Argentina-based accelerator and venture capital fund founded in 2022 that invests in Latin American synthetic biology startups addressing human and planetary preservation challenges.
- Ownership category
- akta.pro rank
SF500 industry classification
Industry- Product category
- Biotechnology Venture Capital
- NAICS
- Open-End Investment Funds (52591)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where SF500 is headquartered
LocationHeadquarters
- HQ city
- Rosario
- HQ country
- Argentina
- HQ region
- Latin America
Markets served
SF500 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
SF500 product offering
Product offeringCore offering
SF500 is an accelerator and venture capital fund that invests in Latin American synthetic biology (synbio) startups whose technologies address global human and planet preservation challenges. The firm deploys capital and provides acceleration support to early-stage synbio companies across the LATAM region, headquartered in Rosario, Argentina.
Differentiator
Problem solved
Functional benefit
Products and services
- SF500 Accelerator Program An accelerator program for early-stage Latin American synthetic biology (synbio) startups, designed to provide mentorship, network access, and operational support to companies tackling human and planetary preservation challenges. Targeted at founders and scientific entrepreneurs from the LATAM synbio ecosystem.
- SF500 Venture Capital Fund A venture capital fund that invests equity capital in Latin American synthetic biology companies whose technologies address human and planet preservation challenges. Targeted at early-stage synbio startups seeking both funding and accelerator support.
Companies that use SF500
Customer profileIdeal customer profiles1 record
SF500 technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SF500 partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights3 records
SF500 competitors and assessment
Company assessmentBroad incumbents
- SOSV: SOSV is the multi-program accelerator and venture firm that operates IndieBio alongside HAX, RebelBio, and others. SF500's hybrid accelerator/VC model directly mirrors SOSV's playbook, making SOSV a relevant incumbent peer across both business model and category.
- Techstars: Techstars is a global accelerator network with multiple industry-specific programs including biotech and sustainability. It is a broader incumbent peer competing for the same pool of mission-driven, science-based founders that SF500 targets.
- Plug and Play: Plug and Play is a global accelerator and VC with dedicated health, biotech, and sustainability verticals and active presence in LATAM. It competes with SF500 both for accelerator deals and corporate-backed VC in the synbio/sustainability space.
- Y Combinator: Y Combinator is the world's largest generalist accelerator, with a growing synbio and biotech vertical. While not category-specific, it competes with SF500 for the same founder talent in LATAM and offers far stronger follow-on capital and network effects.
Direct peers
- IndieBio: IndieBio is the world's leading synthetic biology accelerator, running batch programs and deploying seed capital into synbio startups globally. It is the most direct analogue to SF500's accelerator-plus-VC model in the synbio category, though at far larger scale and US-headquartered.
- At One Ventures: At One Ventures is an early-stage VC focused on deep-tech, synbio, and planet-positive companies. It is a direct peer in the synbio/sustainability-focused VC category and shares SF500's human-and-planet preservation thesis.
- Petri: Petri is an early-stage investor and accelerator dedicated to synthetic biology founders, with a model combining community, capital, and programming. It is a direct peer in the synbio-specific accelerator category that SF500 targets.
- RebelBio: RebelBio is SOSV's pre-seed synthetic biology accelerator, focused on very early-stage synbio teams and offering capital plus lab infrastructure. It directly competes with SF500 for early-stage synbio founders, particularly outside the US.
Emerging players
- 1517 Fund: 1517 Fund is an early-stage venture firm that backs young founders building sci-tech and biotech startups, often at the pre-accelerator stage. It is an emerging peer in the early-stage deep-tech/synbio funding landscape with similar founder-development orientation.
Regional players
- Kaszek Ventures: Kaszek is the largest LATAM-focused venture capital firm, with deep networks across Argentina and Brazil and exposure to deep-tech and biotech. It is a regional peer that competes for the best LATAM founders, including those in synbio-adjacent sectors.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
SF500 social profiles
Digital presenceSF500 financial estimates
Financial estimateRevenue estimate
Valuation estimate
SF500 leadership team
Management profileNumber of profiles
SF500 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SF500 M&A and investment
M&A and investmentM&A
Investments24 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SF500
What does SF500 do?
SF500 is an accelerator and venture capital fund that invests in Latin American synthetic biology (synbio) startups whose technologies address global human and planet preservation challenges. The firm deploys capital and provides acceleration support to early-stage synbio companies across the LATAM region, headquartered in Rosario, Argentina.
Is SF500 a public or private company?
SF500 is a private company. It is classified as unknown and is currently operating.
When was SF500 founded?
SF500 was founded in 2022. It employs 1 to 10 people.
Where is SF500 based?
SF500 is headquartered in Rosario, Argentina, in the Latin America region.
Who are SF500's main competitors?
Broad incumbents on record are SOSV, Techstars, Plug and Play and Y Combinator. Direct peers are IndieBio, At One Ventures, Petri and RebelBio. 1517 Fund is listed as an emerging player. Kaszek Ventures is listed as a regional player.
Does SF500 have an API?
No public API is recorded for SF500.
What industry is SF500 in?
SF500's product category is Biotechnology Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 52591 and its SIC code is 6282.